TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12495409

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed current (HVPC) (100 microseconds, 150 V, 100 Hz) for 45 minutes, 3 times weekly, for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment for 45 minutes, 3 times weekly, for 4 weeks
Number of subjects: 27
Study: 10524422

Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy
Number of subjects: 5569

Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5569
Study: 10142126

Group type: EXPERIMENTAL
Intervention: Consumer-provided case management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonconsumer teams of case managers
Number of subjects: 0
Study: 1718692

Group type: EXPERIMENTAL
Intervention: Gallopamil 0.4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study: 7057507

Group type: EXPERIMENTAL
Intervention: Irrigation with euflavine (spermicide)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Irrigation with sterile water
Number of subjects: 36
Study: 31567357

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVI) irrigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No irrigation (NI)
Number of subjects: 100
Study: 29369348

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (800 mg)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Carbamazepine-CR (200 mg BID)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (1200 mg)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Carbamazepine-CR (400 mg BID)
Number of subjects: 815
Study: 27147223

Group type: EXPERIMENTAL
Intervention: Trampoline exercise + physiotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycling exercise + physiotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Billiard (sham training) + physiotherapy
Number of subjects: 12
Study: 25376394

Group type: EXPERIMENTAL
Intervention: Calorie-labeling present prominently and consistently at main meals for 30 of the 36 weeks (Year 2)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No calorie-labeling (Year 1)
Number of subjects: 240
Study: 23364045

Group type: EXPERIMENTAL
Intervention: Oral Function Improvement Exercises (3 times a week for a total of 24 times)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 19939369

Group type: EXPERIMENTAL
Intervention: Combined sequential acidic and less‐acidic FSH
Number of subjects: 188

Group type: COMPARATOR
Intervention: Less‐acidic FSH (recombinant FSH)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Acidic FSH (human‐derived FSH)
Number of subjects: 188
Study: 18024128

Group type: EXPERIMENTAL
Intervention: Short text of information
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Text read and discussed
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 37
Study: 15332095

Group type: EXPERIMENTAL
Intervention: Activated device (meibomian therapy with latent heat)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inactivated device
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 24
Study: 14972792

Group type: EXPERIMENTAL
Intervention: Cervical cancer patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age matched controls
Number of subjects: 0
Study: 9813877

Group type: EXPERIMENTAL
Intervention: Accumulated oxygen deficit (AOD) measured at 1% treadmill gradient
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Accumulated oxygen deficit (AOD) measured at 10.5% treadmill gradient
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AOD estimated from linear fit of VO2 data
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AOD estimated from curvilinear fit of VO2 data
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VO2max and running economy
Number of subjects: 9
Study: 8132436

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sulpiride (200-400 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paroxetine followed by Sulpiride
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sulpiride followed by Paroxetine
Number of subjects: 50
Study: 2782130

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 96

Group type: COMPARATOR
Intervention: None alcohol consumption
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High sensation seeking
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low sensation seeking
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Moderate alcohol expectancy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: None alcohol expectancy
Number of subjects: 96
Study: 803414

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study: 30711649

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg every 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 0
Study: 29142982

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 10 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 20 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 2.5 mg (multiple dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg (multiple dose)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Etelcalcetide (all doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25956867

Group type: EXPERIMENTAL
Intervention: SIS myringoplasty
Number of subjects: 404

Group type: COMPARATOR
Intervention: PTF myringoplasty
Number of subjects: 404
Study: 23124935

Group type: EXPERIMENTAL
Intervention: Rituximab early
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rituximab late
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rituximab early and late
Number of subjects: 200
Study: 21490520

Group type: EXPERIMENTAL
Intervention: Circumferential injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Single-location injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 64
Study: 18580399

Group type: EXPERIMENTAL
Intervention: Diet + exercise (progressive resistance training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study: 16893438

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study: 15344445

Group type: EXPERIMENTAL
Intervention: Model built using the new approach to model optimisation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Previously published method for building 3D models
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both models used to investigate shape differences
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Model built using the new approach
Number of subjects: 82
Study: 11014136

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment recommendations for bite wounds
Number of subjects: 0
Study: 9358138

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled budesonide (400 microg) plus theophylline (250 or 375 mg depending on body weight)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose inhaled budesonide (800 microg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both treatments (low-dose budesonide plus theophylline and high-dose budesonide)
Number of subjects: 62
Study: 8199605

Group type: EXPERIMENTAL
Intervention: 100 mg of zinc gluconate daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3676055

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine with adrenaline (group Ea)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plain (group Bp)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline (group Ba)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 27
Study: 31845142

Group type: EXPERIMENTAL
Intervention: Image fusion (using CTA and CTC, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (without CTA and CTC reconstruction)
Number of subjects: 80
Study: 30458930

Group type: EXPERIMENTAL
Intervention: ME-401 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ME-401 60 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ME-401 150 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ME-401 (various doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ME-401 once daily 60 mg
Number of subjects: 15
Study: 28190787

Group type: EXPERIMENTAL
Intervention: Riociguat up to 2.5 mg 3 times a day
Number of subjects: 443
Study: 26618449

Group type: EXPERIMENTAL
Intervention: TAE + TVRC(LDSI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: TAE + TVRC
Number of subjects: 58
Study: 22682093

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied around the knee joint during maximal voluntary contraction measurement after vibration.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-taping condition (no Kinesiology tape applied).
Number of subjects: 0
Study: 21682813

Group type: EXPERIMENTAL
Intervention: Pedometer walking plus motivational interviewing (PWMI) program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (leaflet only)
Number of subjects: 64
Study: 19538718

Group type: EXPERIMENTAL
Intervention: Combination Disease Modifying Antirheumatic Drug therapy
Number of subjects: 810

Group type: COMPARATOR
Intervention: Monotherapy methotrexate
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Disease Modifying Antirheumatic Drug of various intensities
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs, hydroxychloroquine, and a single dose of corticosteroids
Number of subjects: 810
Study: 16951642

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI) for 4 months
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control arm (immediate change to optimized antiretroviral regimen)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: STI
Number of subjects: 274
Study: 15305348

Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid (IMDA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (video and information leaflet)
Number of subjects: 201
Study: 11776481

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg, 4 times daily for 2 consecutive days
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 9305557

Group type: EXPERIMENTAL
Intervention: Thromboelastograph (TEG) analysis in morbidly obese patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sonoclot analysis in morbidly obese patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lean controls (N=26)
Number of subjects: 26
Study: 8496384

Group type: EXPERIMENTAL
Intervention: Computerised systems for warfarin control
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Computerised dosage programs
Number of subjects: 186

Group type: COMPARATOR
Intervention: Traditional dosing method by experienced medical staff
Number of subjects: 186
Study: 3100146

Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (53 percent of calories)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fat-based diet (55 percent of calories)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (malnourished patients without COPD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both diets (CB and FB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (CB)
Number of subjects: 15
Study: 29434272

Group type: EXPERIMENTAL
Intervention: Modified Inguinal Microscope-Assisted Varicocelectomy (MIMV)
Number of subjects: 3565

Group type: COMPARATOR
Intervention: Conventional Microsurgical Subinguinal Varicocelectomy (CMSV)
Number of subjects: 3565
Study: 26727957

Group type: EXPERIMENTAL
Intervention: Therapeutic decompressive craniectomy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Prophylactic decompressive craniectomy
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Quality of life measured by EQ-5D
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Intracranial pressure control
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure control
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Incidence of salvage craniectomy in craniotomy patients
Number of subjects: 336
Study: 24880749

Group type: EXPERIMENTAL
Intervention: Lithium (500 mg, twice a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 22493350

Group type: EXPERIMENTAL
Intervention: PEGPH20 (pegylated PH20 hyaluronidase)
Number of subjects: 0
Study: 20627015

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy catheter
Number of subjects: 202
Study: 18841078

Group type: EXPERIMENTAL
Intervention: Dynamic Stretch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ballistic Stretch
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Stretch
Number of subjects: 20
Study: 15596954

Group type: EXPERIMENTAL
Intervention: Rhythm control using antiarrhythmic drugs
Number of subjects: 5175

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 5175

Group type: EXPERIMENTAL
Intervention: Sinus rhythm presence
Number of subjects: 5175
Study: 12527962

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) users during days 15-28
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral contraceptive (OC) users during days 1-14
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normally menstruating women (NM) during follicular phase (FT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normally menstruating women (NM) during luteal phase (LT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normally menstruating women (NM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral contraceptive (OC) users
Number of subjects: 15
Study: 11770139

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8750478

Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous multidrug chemotherapy
Number of subjects: 0
Study: 8325079

Group type: EXPERIMENTAL
Intervention: CB version (chronic bronchitis reference)
Number of subjects: 75

Group type: COMPARATOR
Intervention: NCB version (no chronic bronchitis reference)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 3804883

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 307

Group type: COMPARATOR
Intervention: Gentamicin and Metronidazole
Number of subjects: 307
Study: 29377317

Group type: EXPERIMENTAL
Intervention: ENHANCE trial participation
Number of subjects: 22
Study: 27565734

Group type: EXPERIMENTAL
Intervention: 1800 mg/day of eicosapentaenoic acid (EPA), n = 53
Number of subjects: 107

Group type: COMPARATOR
Intervention: No EPA, n = 54
Number of subjects: 107
Study: 24953916

Group type: EXPERIMENTAL
Intervention: Bupivacaine moistened dressing (12 mL/100 cm2 of 0.25% bupivacaine solution)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional dressing (moistened with normal saline)
Number of subjects: 150
Study: 23297552

Group type: EXPERIMENTAL
Intervention: Series of formulas changed daily according to TCM syndrome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only one formula
Number of subjects: 0
Study: 20546250

Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 3-month healing period
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP with a 4-month healing period
Number of subjects: 31

Group type: COMPARATOR
Intervention: β‐TCP mixed with autologous bone with a 4-month healing period
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhGDF‐5/β‐TCP
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhGDF‐5
Number of subjects: 31
Study: 18166463

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15995113

Group type: EXPERIMENTAL
Intervention: Standard fixed‐bearing knee prosthesis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High‐flexion fixed‐bearing knee prosthesis
Number of subjects: 50
Study: 14575403

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 40
Study: 10229464

Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous transluminal balloon angioplasty (PTA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (observation without treatment)
Number of subjects: 64
Study: 8970500

Group type: EXPERIMENTAL
Intervention: Lithium, starting at 15 mg/kg of body weight, dosage increase every 3 to 4 days until response or serum level of 1.2 to 1.4 mEq/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate (divalproex), initiated at 20 mg/kg of body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine, starting at 200 mg once or twice daily with slow dosage escalation
Number of subjects: 0
Study: 1713269

Group type: EXPERIMENTAL
Intervention: murine monoclonal anti‐CD4 (B‐F5) antibody (10 mg/day, 15 mg/day, 20 mg/day) for 10 consecutive days
Number of subjects: 10
Study: 6711781

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Slow release morphine sulphate tablets (MST, 20 mg)
Number of subjects: 69
Study: 30715637

Group type: EXPERIMENTAL
Intervention: GaAlAs laser treatment (wavelength 830 nm, 30 mW, power density 0.84 W/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LED treatment (wavelength 850 nm, 48 mW, power density 1.05 W/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of laser and LED therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both therapies (laser and LED)
Number of subjects: 0
Study: 29016823

Group type: EXPERIMENTAL
Intervention: Preventive health check with CRF assessment
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Preventive health check without CRF assessment (Control)
Number of subjects: 2201
Study: 27073929

Group type: EXPERIMENTAL
Intervention: Self-sampling using Evalyn Brush or Delphi Screener
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group receiving a 2nd reminder letter
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Self-sampling subgroup
Number of subjects: 800
Study: 23643048

Group type: EXPERIMENTAL
Intervention: Progressive resistance, whole body long-axis rotational training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 36
Study: 22158074

Group type: EXPERIMENTAL
Intervention: Serum HSP70 levels in pancreatic cancer patients (PC)
Number of subjects: 45
Study: 20439348

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 37
Study: 17272969

Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 15665005

Group type: EXPERIMENTAL
Intervention: Home based medication review by pharmacists (two home visits within two weeks and eight weeks of discharge)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Home based medication review by pharmacists
Number of subjects: 872
Study: 12177661

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 10453419

Group type: EXPERIMENTAL
Intervention: High-dose pancreatin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard-dose pancreatin
Number of subjects: 39
Study: 7885907

Group type: EXPERIMENTAL
Intervention: Breast self-examination awareness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast awareness
Number of subjects: 0
Study: 2358266

Group type: EXPERIMENTAL
Intervention: 1% MK‐417
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1% MK‐927
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (common vehicle)
Number of subjects: 27
Study: 402569

Group type: EXPERIMENTAL
Intervention: Segontin-Digoxin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 30
Study: 31680631

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 696
Study: 31265450

Group type: EXPERIMENTAL
Intervention: 1FOOT (1 day of 60-min 5 vs 5 football)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3FOOT (3 consecutive days of 60-min 5 vs 5 football)
Number of subjects: 18
Study: 28040445

Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up (AF) group
Number of subjects: 700

Group type: COMPARATOR
Intervention: Clinical follow-up alone (CF) group
Number of subjects: 700
Study: 26586819

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo conditioning
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham mindfulness meditation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Book-listening control intervention
Number of subjects: 75
Study: 24000709

Group type: EXPERIMENTAL
Intervention: Treatment for community-acquired pneumonia with hypertension
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (patients with community-acquired pneumonia during treatment)
Number of subjects: 60
Study: 22619907

Group type: EXPERIMENTAL
Intervention: 75-mg of diclofenac sodium
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 46
Study: 20553075

Group type: EXPERIMENTAL
Intervention: Cases (3,144)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controls (10,661)
Number of subjects: 3